Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Joseph H. Porter"'
Autor:
Todd M. Hillhouse, Christina R. Merritt, Douglas A. Smith, Manuel Cajina, Connie Sanchez, Joseph H. Porter, Alan L. Pehrson
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Attention impairment is a common feature of Major Depressive Disorder (MDD), and MDD-associated cognitive dysfunction may play an important role in determining functional status among this patient population. Vortioxetine is a multimodal antidepressa
Externí odkaz:
https://doaj.org/article/084468889a0a4ae09969c2ddabed7b72
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0301848 (2024)
Ketamine has been shown to produce analgesia in various acute and chronic pain states; however, abuse liability concerns have limited its utility. The ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) has been shown to produce antidepressant-like
Externí odkaz:
https://doaj.org/article/1bc94511a1634c1eb7b0738d84a673d3
Autor:
Mohammed A. Mustafa, Justin L. Poklis, Kimberly N. Karin, Jayden A. Elmer, Joseph H. Porter, Victoria Parra, Dai Lu, Joel E. Schlosburg, Aron H. Lichtman
Publikováno v:
Cannabis and Cannabinoid Research.
Publikováno v:
Psychopharmacology, 239(6), 1853-1879. Springer
Rationale Recent trials with psychedelics in major depressive disorder and treatment-resistant depression showed remarkable improvements in depressive symptoms that can last for up to several months after even a single administration. The lack of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45776b01516593a199bab2007e965cf1
https://cris.maastrichtuniversity.nl/en/publications/d6962d9d-89c7-4d4c-9029-e929923566cb
https://cris.maastrichtuniversity.nl/en/publications/d6962d9d-89c7-4d4c-9029-e929923566cb
Autor:
Fan Zhang, Tegshjargal Baasansukh, Keith L. Shelton, Joseph H. Porter, Katherine L. Nicholson
Publikováno v:
The FASEB Journal. 36
Autor:
Joseph H. Porter, Julia Blumenstein, James T Cooper, Carson T Clark, Cayla J Lynch, Rodney A. Hansen, Noah Gelfman, Todd M. Hillhouse, Makenzie L Peterson
Publikováno v:
Journal of American college health : J of ACH.
Objective The present study evaluated the effects of nicotine concentration (0-10 mg/ml) and flavor (gummy bear vs unflavored) on the subjective experiences of vaporized nicotine in young adult low-dose nicotine (3 mg/ml) ECIG users. Participants Eig
Autor:
Joseph H. Porter, Todd M. Hillhouse, Taylor N. Kegen, Fan Zhang, Elizabeth Pottanat, Paige M. Anderson, Madeline Van Fossen, Peyton O. Koppenhaver, Sofia G. Manicka, Remington Rice, Jackson T. Lane
Publikováno v:
Pharmacology, biochemistry, and behavior. 208
In 2000, a subanesthetic dose (0.5 mg/kg i.v.) of the dissociative anesthetic ketamine was reported to have both rapid and robust antidepressant effects in patients diagnosed with major depressive disorder and later, ketamine also was shown to be eff
Autor:
Priyodarshan Goswamee, Remington Rice, Elizabeth Leggett, Fan Zhang, Sofia Manicka, Joseph H. Porter, A. Rory McQuiston
Publikováno v:
Neuropharmacology
Acute cognitive impairment and abuse potential of ketamine incentivizes the search for alternatives to ketamine for clinical management of treatment-resistant depression. Recently, (2R,6R) hydroxynorketamine ((2R,6R)-HNK), a metabolite of ketamine, h
Publikováno v:
British Journal of Pharmacology. 176:3886-3888
Autor:
Timothy J. Donahue, Kevin A. Webster, Eliseu O. De Oliveira, Todd M. Hillhouse, Joseph H. Porter
Publikováno v:
Behavioural pharmacology. 30(6)
Haloperidol (HAL) was developed in 1958 for the treatment of schizophrenia and is classified as a typical antipsychotic drug (APD). Effective in treating positive symptoms of schizophrenia, it does not treat negative symptoms and produces extrapyrami